Epidemic Trends of Obesity with Impact on Metabolism and Digestive Diseases

Feneberg, Anja C.; Malfertheiner, Peter

doi:10.1159/000336660

Cited by 20 publications

(10 citation statements)

References 43 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results with its use correlate well with other markers of obesity, such as waist circumference and waist-to-hip ratio. 2 The increased risk for obese persons has been clearest for cardiovascular (CV) diseases, 1,4,[16][17][18] but increased risks for other conditions have been reported, including liver disease, 19 kidney disease, 20 diabetes mellitus, 21 and some types of cancer. [22][23][24] Arguably, the obesity epidemic may be leveling off, 25 but it remains a major public and individual health concern.…”

Section: Introductionmentioning

confidence: 99%

Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight?

Klatsky

Zhang²,

Udaltsova³

et al. 2017

TPJ

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight?

Klatsky

Zhang²,

Udaltsova³

et al. 2017

TPJ

View full text Add to dashboard Cite

show abstract

“…T2DM and NAFLD (T2DM-NAFLD) are components of the metabolic syndrome, a cluster of interrelated clinical features including insulin resistance, dyslipidemia, hypertension, and visceral obesity [12] . T2DM and NAFLD are major health issues associated with the worldwide epidemic of obesity [13] . Insulin resistance plays a major role in the pathogenesis of T2DM-NAFLD and is considered a key factor in the initiation and perpetuation of NASH [14] .…”

Section: Introductionmentioning

confidence: 99%

Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

et al. 2015

WJG

View full text Add to dashboard Cite

AIM:To explore the mechanism of action of gypenosides (GPs) on type 2 diabetes mellitus and non-alcoholic fatty liver disease (T2DM-NAFLD) in rats. METHODS:Sixty rats were randomly divided into a healthy group, an untreated disease model group and GP-treatment groups. The study involved the evaluation of biochemical parameters, including serum aspartate transaminase (AST), alanine transferase (ALT), blood glucose (BG), triglycerides (TG) and total cholesterol (TC). Additionally, the protective effect of the treatments were confirmed histopathologically and the expression of TNF-α and NF-κB in the rat liver was analyzed using immunohistochemistry. The expression of proliferatoractivated receptor gamma (PPARγ) and cytochrome P450 (CYP450) 1A1 mRNA was determined by quantitative RT-PCR. RESULTS:GP treatments at oral doses of 200, 400, and 800 mg/kg per day significantly decreased the levels of serum AST and ALT (P < 0.05, P < 0.01), especially at the dose of 800 mg/kg per day. To a similar extent, GP at 800 mg/kg per day reduced the levels of BG (4.19 ± 0.47, P < 0.01), TG (80.08 ± 10.05, P < 0.01), TC (134.38 ± 16.39, P < 0.01) and serum insulin (42.01 ± 5.04, P < 0.01). The expression of TNF-α and NF-κB measured by immunohistochemistry was significantly reduced by GPs in a dose-dependent manner, and the expression of PPARγ and CYP4501A1 mRNA, as measured using quantitative real-time PCR, were significantly down-regulated by GPs. Moreover, GPs decreased the infiltration of liver fats and reversed the histopathological changes in a dosedependent manner. CONCLUSION:This study suggests that GPs have a protective effect against T2DM-NAFLD by down-regulating the expression of TNF-α and NF-κB proteins, and PPARγ and CYP4501A1 mRNAs. Core tip: Gypenosides (GPs) are one of the most pharmacologically active components in G. pentaphyllum . Basic Study ORIGINAL ARTICLEHe Q et al . Mechanism of action of GPs on T2DM-NAFLD Intervention with GPs significantly decreased the levels of aspartate aminotransferase, alanine aminotransferase, blood glucose, insulin, triglycerides and total cholesterol in type 2 diabetes mellitus and non-alcoholic fatty liver disease (T2DM-NAFLD) model rats, down-regulated the expression of TNF-α, NF-κB, rabbit anti-proliferator activated receptory (PPARγ) and rabbit anti-cytochrome P4501A1 (CYP1A1) mRNA, decreased the infiltration of liver fats and reversed the histopathological changes in a dose-dependent manner. These findings suggest that GPs have a protective effect against T2DM-NAFLD by downregulating the expression of TNF-α and NF-κB proteins, and PPARγ and CYP4501A1 mRNAs.He Q, Li JK, Li F, Li RG, Zhan GQ, Li G, Du WX, Tan HB. Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats.

show abstract

“…The numbers of patients attending diabetic clinic in Tikur Anbessa Specialized Hospital during study period were 850 while patients visiting Federal Referral Police Hospital were 1250. The data were collected from January 2015 to March 2015 [26][27][28][29][30][31][32][33][34][35][36].…”

Section: Methods and Subjectsmentioning

confidence: 99%

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Dango¹,

Umeta²

2016

JPP

View full text Add to dashboard Cite

Epidemic Trends of Obesity with Impact on Metabolism and Digestive Diseases

Cited by 20 publications

References 43 publications

Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight?

Body Mass Index and Mortality in a Very Large Cohort: Is It Really Healthier to Be Overweight?

Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

Profiles of Liver Function Tests among Type 2 Diabetic Patients Who are Receiving Different Anti-Diabetic Drugs Attending Tikur Anbessa Specialized Hospitals

Contact Info

Product

Resources

About